Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial-Reference-Cited by-同舟云学术

Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial

Published:2023-09 Issue: Volume:191 Page:112984
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Brugières Laurence,Cozic Nathalie,Houot Roch,Rigaud Charlotte,Sibon David,Arfi-Rouche Julia,Bories Pierre,Cottereau Anne S.,Delmer Alain,Ducassou Stephane,Garnier Nathalie,Lamant Laurence,Leruste Amaury,Millot Frederic,Moalla S.,Morschhauser Franck,Nolla Marie,Pagnier Anne,Reguerre Yves,Renaud Loic,Schmitt Anne,Simonin Mathieu,Verschuur Arnaud,Hoog Labouret Nathalie,Mahier Ait Oukhatar Celine,Vassal Gilles

Funder

Pfizer

ARC Foundation for Cancer Research

French National Cancer Institute

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference31 articles.

1. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group;Brugières;J Clin Oncol,2009

2. ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients;Sibon;Haematologica,2019

3. Peripheral T-cell lymphomas: therapeutic approaches;Sibon;Cancers ((Basel)).,2022